ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,900Medicare Part D Prescriptions Filled, Including Refills

Rank: 112 out of 617

$565K Total Retail Price of All Prescriptions

Rank: 63 out of 617

272 Patients Receiving at Least One Drug in Part D
79%Patients 65 Years and Older
52% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

14% of this provider’s 272 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

18% of this provider’s 272 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

1% of this provider’s 7,821 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

29% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$57 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

36 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
LEVOTHYROXINE SODIUM 454 383 1 1
OMEPRAZOLE 418 296 2 3
FENTANYL 294 271 S2 3 45
SIMVASTATIN 277 185 4 2
WARFARIN SODIUM 238 206 5 7
HYDROCODONE-ACETAMINOPHEN 203 147 S3 6 8
TRAMADOL HCL 198 185 7 15
FUROSEMIDE 189 173 8 4
MIRTAZAPINE 182 182 9 50
LISINOPRIL 178 156 10 5
SERTRALINE HCL 176 163 11 20
AMLODIPINE BESYLATE 160 150 12 6
POLYETHYLENE GLYCOL 3350 150 132 13 32
DIOVAN 140 130 14 41
METFORMIN HCL 137 111 15 9
HYDROCHLOROTHIAZIDE 134 110 16 13
POTASSIUM CHLORIDE 133 107 17 10
METOPROLOL TARTRATE 129 129 18 11
GABAPENTIN 120 85 19 16
MELOXICAM 117 93 20 24
CLONIDINE HCL 103 103 21 55
ALLOPURINOL 103 65 21 27
METOPROLOL SUCCINATE 102 88 23 12
CARVEDILOL 97 88 24 19
ATORVASTATIN CALCIUM 93 57 25 14
CYMBALTA 92 51 26 49
FLUTICASONE PROPIONATE 90 66 27 36
VESICARE 82 81 28 95
EXELON 78 78 29 156
NEXIUM 72 61 30 43
CRESTOR 71 59 31 28
DIGOXIN 70 70 32 48
BUMETANIDE 68 66 33 124
GLIMEPIRIDE 68 55 33 33
NAMENDA 68 68 33 35
KLOR-CON 10 68 66 33 126
DONEPEZIL HCL 66 66 37 30
AMLODIPINE BESYLATE-BENAZEPRIL 65 65 38 80
LEVOFLOXACIN 62 57 39 89
BYSTOLIC 61 44 40 64
LYRICA 60 32 41 92
FENOFIBRATE 60 44 41 58
LISINOPRIL-HYDROCHLOROTHIAZIDE 60 57 41 29
ALENDRONATE SODIUM 59 59 44 25
WELCHOL 58 55 45 170
OXYBUTYNIN CHLORIDE ER 57 24 46 114
TAMSULOSIN HCL 56 33 47 26
RAMIPRIL 55 34 48 67
AVODART 53 53 49 144
ULORIC 53 53 49 310
QUETIAPINE FUMARATE 52 37 51 78
SPIRIVA 50 43 52 61
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 22, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.